Addex Therapeutics annual stock-based compensation
2017
2018
2019
2020
2021
2022
2023
2024
Addex Therapeutics Stock-Based Compensation Growth & History (ADXN)
Addex Therapeutics's stock-based compensation was CHF17,544 for fiscal 2024.
View full Addex Therapeutics company overviewAddex Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | CHF17,544 | −CHF12,377 | −41.37% |
| 2023 | 2023-12-31 | CHF29,921 | −CHF19,320 | −39.24% |
| 2022 | 2022-12-31 | CHF49,241 | −CHF897,391 | −94.80% |
| 2021 | 2021-12-31 | CHF946,632 | CHF45,207 | +5.02% |
| 2020 | 2020-12-31 | CHF901,425 | −CHF409,463 | −31.24% |
| 2019 | 2019-12-31 | CHF1.3M | CHF591,514 | +82.23% |
| 2018 | 2018-12-31 | CHF719,374 | CHF635,915 | +761.95% |
| 2017 | 2017-12-31 | CHF83,459 | — | — |
Addex Therapeutics quarterly stock-based compensation
Q2.21
Q2.22
Q2.23
Q2.24
Q2.25
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2025 | 2025-06-30 | CHF1,851 | −CHF2,850 | −60.63% |
| Q2 2024 | 2024-06-30 | CHF4,701 | −CHF412,246 | −98.87% |
| Q2 2023 | 2023-06-30 | CHF416,947 | −CHF133,274 | −24.22% |
| Q2 2022 | 2022-06-30 | CHF550,221 | CHF289,245 | +110.83% |
| Q2 2021 | 2021-06-30 | CHF260,976 | — | — |
Addex Therapeutics stock-based compensation trends
Over the last five fiscal years, Addex Therapeutics's stock-based compensation decreased from CHF1.3M to CHF17,544, a change of −CHF1.3M. The latest reported quarter, Q2 2025, shows CHF1,851.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Addex Therapeutics source filings ↗